Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2758)	6/6/2012 11:38:44 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

Here's one EULAR-Berlin release that has a nice aside..... finance.yahoo.com >> DAS28 is a measure of disease activity in RA. The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (a marker of systemic inflammation), and the patient’s ‘global assessment of global health’ (indicated by marking a 10 cm line between ‘very good’ and ‘very bad’). A DAS28 score greater than 5.1 indicates severe active disease, less than 3.2 low disease activity, and less than 2.6 DAS28 remission. << and this, 24 weeks on anti-IL-6R, no previous biologics...... >> a DAS28 remission rate of 40 percent with ACTEMRA versus 11 percent with adalimumab (DAS28 <2.6) <<